**HPTN 083**

**Active Products**
- Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral FTC/TDF

**Populations**
- 4,570 cisgender men and transgender women who have sex with men

**Locations**
- Argentina, Brazil, Peru, South Africa, Thailand, U.S., Vietnam

**Start Date**
- December 2016

**Study Design**
- Non-Inferiority of CAB LA to FTC/TDF
  - A non-inferiority study tests whether one drug works about the same as, but not worse than, another drug
  - The study showed superiority of CAB LA over oral FTC/TDF, meaning CAB LA worked better to prevent HIV infection in the population than oral FTC/TDF.

**Study Steps**
- **STEP 1**
  - 5 weeks of 2 daily oral pills – 1 active and 1 placebo
- **STEP 2**
  - Injections every 8 weeks and daily pills for up to 3 years
- **STEP 3**
  - Daily oral pills for 48 weeks

**Study Results**
- There was a 66% reduction in HIV infections in study participants provided CAB compared to FTC/TDF.

---

**HPTN 084**

**Active Products**
- Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral FTC/TDF

**Populations**
- 3,200 (projected) cisgender women

**Locations**
- Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda, Zimbabwe

**Start Date**
- November 2017

**Study Design**
- Superiority of CAB LA to FTC/TDF
  - A superiority study tests whether one drug works better than another drug
  - The study showed superiority of CAB LA over oral FTC/TDF, meaning CAB LA worked better to prevent HIV infection in the population than oral FTC/TDF.

**Study Steps**
- **STEP 1**
  - 5 weeks of 2 daily oral pills – 1 active and 1 placebo
- **STEP 2**
  - Injections every 8 weeks and daily pills for up to 3 years
- **STEP 3**
  - Daily oral pills for 48 weeks

**Study Results**
- There was a 89% reduction in HIV infections in study participants provided CAB compared to FTC/TDF.